Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
Apellis Pharmaceuticals (APLS) stock surged 5.8% in the last trading session, driven by investor optimism surrounding its drug Empaveli, which generated strong Q4 2025 revenues. The company is expected to report a smaller loss per share compared to the previous year, and positive revisions in earnings estimates suggest potential for further stock appreciation. The stock currently holds a Zacks Rank #3 (Hold).
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left
Apellis Pharmaceuticals shares have been delisted from Nasdaq following Biogen's $5.6 billion acquisition. Investors received $41 per share in cash, plus a Contingent Value Right (CVR) tied to future sales of Apellis's drugs, Syfovre and Empaveli. The focus now shifts to Biogen's ability to generate significant revenue from these drugs to justify the acquisition, with the CVR offering potential additional payouts if sales milestones are met.
Biogen–Apellis (APLS) deal triggers GC’s cash, CVR and option changes
Apellis Pharmaceuticals' General Counsel, David O. Watson, reported multiple stock and option transactions as a mechanical effect of the company's acquisition by Biogen. Shareholders received $41.00 in cash per share plus one contingent value right (CVR) potentially worth an additional $4.00. The filing details how various equity awards, including RSUs and stock options, were converted or canceled based on the merger agreement.
Deep Track (APLS) reports 4.53M shares, a 3.55% stake
Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,532,374 shares of Apellis Pharmaceuticals (APLS) common stock, representing a 3.55% stake. The filing indicates shared voting and dispositive power over these shares, referencing 127,829,909 shares outstanding as of February 17, 2026. This administrative amendment serves as routine disclosure of their passive investment and does not signal an active change in strategy.
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS)
RTW Investments, LP and Roderick Wong have filed an amended passive investment disclosure (Schedule 13G/A) for Apellis Pharmaceuticals, Inc. (APLS), reporting beneficial ownership of 3,685,045
Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals
Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, excluding fees. Apellis shareholders received $41.00 per share in cash plus a contingent value right up to $4.00 based on SYFOVRE® sales milestones. Apellis' common stock has been suspended from trading on Nasdaq and will be delisted.
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR
Apellis Pharmaceuticals director Dunlop A. Sinclair has disposed of all reported equity interests following the company's merger with Biogen. Shareholders who tendered common shares received $41.00 in cash per share plus one contingent value right (CVR), offering potential additional payments of up to $4.00 per share based on milestone achievements. Stock options were either cancelled for cash and CVRs if their exercise price was below $41.00, or cancelled without consideration if at or above $45.00.
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity
Apellis Pharmaceuticals director Paul R. Fonteyne reported the disposal of his equity interests following Biogen's acquisition of Apellis. This Form 4 details transactions where Apellis common stock was exchanged for cash and contingent value rights (CVRs), and stock options were either converted to cash and CVRs or cancelled without consideration. Following these transactions, Fonteyne's reported holdings show zero shares remaining.
Biogen deal: Apellis (APLS) director’s shares and options cashed out
Apellis Pharmaceuticals director Keli Walbert has disposed of her entire stake in the company, including common stock and stock options, as part of Biogen's acquisition of Apellis. Under the merger agreement, shares were exchanged for $41.00 in cash plus one contingent value right (CVR) potentially worth an additional $4.00, and stock options with exercise prices below $41.00 were cashed out. Following these transactions, Walbert holds no directly owned Apellis common shares or stock options.
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR
Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported the disposition of shares and stock options following Biogen's acquisition of Apellis. According to the merger terms finalized on May 14, 2026, Apellis shareholders received $41.00 cash per share plus one contingent value right (CVR) that could pay up to an additional $4.00, while stock options were either cashed out or cancelled based on their exercise price. All of O'Brien's reported common stock and options in Apellis were converted or cancelled as a result of these transactions.
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap
Apellis Pharmaceuticals director Craig A. Wheeler has fully divested his stake in the company as part of its merger with Biogen. This included the disposal of common shares and cancellation of vested stock options, with each common share exchanged for $41.00 in cash plus one contingent value right potentially worth up to an additional $4.00. Following these transactions, Wheeler no longer holds any Apellis common stock or stock options.
Biogen Completes Acquisition of Apellis Pharmaceuticals
Biogen Inc. has successfully completed its acquisition of Apellis Pharmaceuticals, a move expected to significantly enhance Biogen's near-term growth and expand its presence in nephrology. The acquisition adds two commercialized products, EMPAVELI® and SYFOVRE®, which generated $689 million in net revenue in 2025. This transaction is projected to be accretive to Biogen's Non-GAAP diluted EPS by 2027 and materially increase its non-GAAP EPS compound annual growth rate through the end of the decade.
Biogen to acquire Apellis for $5.6bn
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, aiming to expand its presence in complement-mediated diseases. The deal, unanimously approved by both boards, includes a cash tender offer of $41 per share and contingent value rights tied to Syfovre's sales milestones. This acquisition is expected to enhance Biogen’s growth portfolio and be accretive to its non-GAAP diluted earnings per share from 2027.
State Street (APLS) discloses 6.85M shares, 5.4% holding
State Street Corporation has disclosed a passive ownership of 5.4% in Apellis Pharmaceuticals (APLS), comprising 6,845,031 shares as of March 31, 2026. The filing, a Schedule 13G, indicates shared voting power of 6,603,712 shares and shared dispositive power of 6,845,031 shares among various State Street-related entities. This ownership is typical for asset managers and does not suggest an intent to control the company.
Apellis (APLS) HSR waiting period expired; $41.00 cash plus up to $4.00 CVR
Apellis Pharmaceuticals has announced that the Hart-Scott-Rodino (HSR) waiting period for its tender offer and merger has expired as of May 11, 2026, satisfying a key regulatory condition. This paves the way for the acquisition by a Biogen subsidiary, which proposes $41.00 per share in cash plus a non-transferable contingent value right (CVR) for up to $4.00 in additional cash based on milestone achievements. The expiration removes an antitrust obstacle, but final closing depends on other conditions.
The Technical Signals Behind (APLS) That Institutions Follow
This article analyzes the technical signals for Apellis Pharmaceuticals Inc. (NASDAQ: APLS), indicating a neutral near and mid-term outlook that could moderate a long-term positive bias. It highlights elevated downside risk due to a lack of additional long-term support signals and provides institutional trading strategies for position trading, momentum breakout, and risk hedging. The analysis is based on AI models and offers multi-timeframe signal insights for various holding periods.
Apellis set to report earnings ahead of Biogen deal closes
Apellis Pharmaceuticals is scheduled to release its first-quarter earnings before the completion of Biogen's $5.6 billion acquisition. Analysts anticipate a loss of 34 cents per share on revenue of $203.58 million, and investors will be closely monitoring the growth trajectory of Syfovre and commentary on the deal's timeline, particularly regarding the contingent value rights tied to future sales milestones.
Apellis set to report earnings ahead of Biogen deal closes
Apellis Pharmaceuticals Inc. is set to announce its first-quarter earnings, likely its last as an independent entity before Biogen completes its $5.6 billion acquisition. Analysts project a loss of 34 cents per share on revenue of $203.58 million, with particular attention on Syfovre's sales trajectory to meet contingent value rights (CVR) milestones tied to the Biogen deal. Investors will also monitor commentary regarding the deal's closing timeline and Apellis's path to profitability.
Is It Too Late To Consider Apellis Pharmaceuticals (APLS) After Its 130% One Year Surge?
Apellis Pharmaceuticals (APLS) has seen a 130% surge over the last year, sparking questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is 63.3% undervalued, with an estimated intrinsic value of $111.61 per share compared to its current price of $41.01. However, its P/E ratio of 39.39x is higher than the industry average, indicating it might be overvalued by this metric.
Apellis Pharmaceuticals (APLS) Q1 Profitability Reinforces Bullish Earnings Quality Narrative
Apellis Pharmaceuticals (APLS) reported Q1 2026 revenue of US$268.3 million and a net income of US$18.7 million, yielding a basic EPS of US$0.15. This performance aligns with improving earnings quality and tighter net profit margins over recent quarters, following a period of volatility. While revenue growth of 10.3% lags the broader US market, the company's shift to profitability and improved net margins are positive signs for bullish investors, though concerns remain regarding product concentration and market volatility.
Apellis Pharmaceuticals (APLS) Q1 Profitability Reinforces Bullish Earnings Quality Narrative
Apellis Pharmaceuticals reported strong Q1 2026 results with US$268.3 million in revenue and US$0.15 basic EPS, contributing to a positive trailing 12-month net income of US$133.3 million. This marks a shift to profitability after previous losses, with bulls emphasizing improved earnings quality and net profit margins. Bears, however, are concerned about revenue growth trailing market benchmarks and product concentration risks.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) exceeded Q1 earnings and revenue estimates, reporting $0.15 per share against an expected loss of $0.38, and revenues of $268.3 million, topping estimates by 33.65%. The company's shares have gained 63.7% year-to-date, significantly outperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold).
Apellis Pharmaceuticals stock hits 52-week high at 41.04 USD
Apellis Pharmaceuticals Inc. (APLS) has hit a new 52-week high of $41.04 USD, marking a significant 127.74% increase in stock price over the past year and bringing its market capitalization to $5.24 billion. Despite this, some analyses suggest the stock may be overvalued, trading at a P/E ratio of 237.65. Recent analyst actions have followed an acquisition agreement with Biogen, where Biogen is set to purchase Apellis for $41 per share in cash, plus contingent value rights, leading to updated ratings and price targets from firms like Mizuho, Roth/MKM, and Raymond James.
[SC TO-T/A] Apellis Pharmaceuticals, Inc. Amended Third-Party Tender Offer | APLS SEC Filing - Form SC TO-T/A
This SEC filing (Form SC TO-T/A) is an amendment to a tender offer statement by Biogen Inc. for all outstanding shares of Apellis Pharmaceuticals, Inc. The amendment provides updates on financial advisory services and discloses additional lawsuits and demand letters from purported stockholders alleging disclosure deficiencies related to the proposed transactions. Biogen and Apellis maintain that the allegations are without merit and disclosures comply with applicable law.
Apellis Pharmaceuticals, Inc. Amended Tender Offer Recommendation [SC 14D9/A]
Apellis Pharmaceuticals, Inc. has filed Amendment No. 1 to its Schedule 14D-9, supplementing disclosures related to Biogen's tender offer to acquire all outstanding shares of Apellis common stock. The amendment provides additional information regarding potential legal proceedings and updates financial projections and analyses. Specifically, it addresses three lawsuits filed by purported stockholders alleging misrepresentation and omission of material information from previously filed documents.
Assessing Apellis Pharmaceuticals (APLS) Valuation After Recent Share Price Momentum And Contrasting Fair Value Views
Apellis Pharmaceuticals (APLS) has seen significant share price momentum recently, with a 76.98% return over 90 days and 114.28% over one year, bringing its stock to $40.97. While analyst consensus views the stock as fairly valued at $40.93 based on projected future earnings and revenues, Simply Wall St's Discounted Cash Flow model suggests a significantly higher fair value of $111.83, raising questions about whether the market is undervaluing the company's future cash flow potential. The article encourages investors to look beyond current narratives and consider underlying data and potential risks or upsides.
Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions
Apellis Pharmaceuticals, Inc. filed an 8-K report detailing amendments to its executive separation plan in connection with its merger with Biogen Inc. The changes ensure accelerated vesting of equity awards and broadened "good reason" provisions for C-level executives upon merger completion or executive departures. Investors should monitor these changes as they could lead to significant payouts and impact the financial aspects of the merger for both companies.
Top 3 Health Care Stocks That May Collapse This Month
This article highlights three healthcare stocks - Avanos Medical Inc (AVNS), Apellis Pharmaceuticals Inc (APLS), and Cerus Corp (CERS) - that are currently considered overbought based on their high RSI values. These companies have recently seen significant stock gains due to acquisition announcements and strong financial performance. The article suggests that their high momentum might indicate a potential for collapse for investors focused on momentum trading.
Apellis Cell And Gene Update Puts Growth Story In Investor Focus
Apellis Pharmaceuticals is set to present its cell and gene therapy programs at the 2026 Cell & Gene Meeting on the Mediterranean, drawing attention to its potential growth beyond existing products. Investors will be looking for details on clinical development, timelines, and how these programs differentiate Apellis within the competitive biotech landscape. The company faces risks like access barriers and share price volatility, but analysts see good value and growth potential from its pipeline.
Apellis Cell And Gene Update Puts Growth Story In Investor Focus
Apellis Pharmaceuticals will present at the 2026 Cell & Gene Meeting on the Mediterranean, highlighting its cell and gene therapy programs. This presentation offers investors insights into how Apellis's complement biology expertise is expanding into new therapeutic areas, potentially broadening its market beyond existing products like SYFOVRE and EMPAVELI. While analysts note risks such as access barriers and pricing pressures, they also see growth potential and value compared to peers.
UBS Group AG Boosts Stake in Apellis Pharmaceuticals, Inc. $APLS
UBS Group AG recently increased its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 22.1% in the fourth quarter, now owning 3.31% of the company worth approximately $105.16 million. Despite high institutional ownership and a recent EPS beat, current analyst sentiment is a "Hold" rating with an average price target below the stock's recent trading price. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for rare eye, blood, and kidney diseases.
Universal Beteiligungs und Servicegesellschaft mbH Purchases 49,642 Shares of Apellis Pharmaceuticals, Inc. $APLS
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Apellis Pharmaceuticals, Inc. by purchasing 49,642 additional shares in the fourth quarter, bringing its total holding to 95,755 shares valued at approximately $2.405 million. Apellis reported a stronger-than-expected Q4 EPS of $0.47 and revenues of $199.91 million, though its year-over-year revenue decreased by 5.9%. Despite high institutional ownership and several funds increasing their positions, analysts maintain a consensus "Hold" rating on the stock with an average price target of $34.89, following recent downgrades from several brokerages.
Jennison Associates LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. $APLS
Jennison Associates LLC significantly reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 65.4% in the fourth quarter, selling over 2.8 million shares. This move leaves them with 1.5 million shares valued at approximately $37.79 million. Despite this reduction, Apellis recently reported better-than-expected quarterly earnings, beating analyst estimates with $0.47 EPS on revenues of $199.91 million, although revenue was down slightly year-over-year.
Apellis Pharmaceuticals, Inc. (APLS) expected to beat earnings estimates: Should you buy?
Apellis Pharmaceuticals (APLS) is projected to surpass its upcoming quarterly earnings estimates, with the Zacks Consensus Estimate at a loss of $0.62 per share, indicating a 67.4% year-over-year improvement. Revenue is also expected to significantly increase to $117.84 million, up 163.7% from the prior-year quarter. Investors should monitor the stock's price movement around the announcement, as a recent upward revision in estimates suggests potential for an earnings beat.
Apellis (NASDAQ: APLS) CMO reports bona fide gift of 900 shares
Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, reported a bona fide gift of 900 shares of common stock. These shares were transferred as a charitable contribution at no price. Following this transaction, Ms. Baumal directly holds 86,525 shares, maintaining a substantial equity stake in the company.
M&T Bank Corp Has $1.38 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS
M&T Bank Corp significantly increased its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 322.8% in Q4, acquiring an additional 42,041 shares to hold a total of 55,066 shares valued at approximately $1.38 million. Apellis Pharmaceuticals reported stronger-than-expected quarterly earnings, but the stock trades near its 1-year high with a high P/E ratio, and analysts currently maintain a consensus "Hold" rating for the company.
APLS: Biogen Deal Terms And Mixed Ratings Will Guide Future Repricing
Analysts have adjusted the fair value estimate for Apellis Pharmaceuticals to approximately $40.93, influenced by mixed analyst ratings after Biogen's acquisition announcement. Bullish outlooks highlight the potential of key products and market share gains, while bearish perspectives focus on execution risks and conservative growth assumptions. This deal, valued at $41 per share plus contingent payments, is expected to close in the second quarter of 2026.
Apellis Pharmaceuticals stock hits 52-week high at $40.96
Apellis Pharmaceuticals Inc. (APLS) stock reached a 52-week high of $40.96, reflecting a 1-year change of 124.88% and strong investor confidence. This performance comes amidst developments including Biogen's plan to acquire Apellis for $41 per share, leading several analyst firms to adjust ratings and price targets. The acquisition, valued at $5.6 billion in upfront equity, is seen as a favorable outcome for Apellis shareholders.
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Wednesday
Apellis Pharmaceuticals (APLS) is slated to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts projecting a loss of ($0.38) per share and revenues of $203.5850 million. The company previously exceeded expectations in Q4 2025, reporting $0.47 EPS against a consensus of ($0.39). Despite a recent stock performance near a 1-year high, the average analyst rating remains "Hold" with a price target of $34.89.
Apellis earnings up next: Last report before Biogen takeover?
Apellis Pharmaceuticals is set to report its first-quarter earnings, which could be its last as an independent company before Biogen completes its $5.6 billion acquisition. Analysts anticipate a loss of 34 cents per share on revenue of $203.6 million, a reversal from the previous quarter's surprise profit. Investors will be seeking updates on the acquisition timeline and regulatory clearances, as well as insights into Syfovre sales trends and potential contingent value rights payouts.
Apellis Pharmaceuticals stock hits 52-week high at $40.96 By Investing.com
Apellis Pharmaceuticals Inc. stock recently achieved a 52-week high of $40.96, marking a significant performance milestone with a 1-year change of 124.88%. This rise is supported by positive company developments and investor confidence. The company is also undergoing an acquisition by Biogen for $41 per share in cash, plus contingent value rights, prompting analyst rating adjustments.
Apellis (NASDAQ: APLS) outlines 2025 executive pay, board and risk oversight
Apellis Pharmaceuticals filed an amended annual report (10-K/A) to detail its 2025 executive compensation and corporate governance, which includes a nine-member classified board and four key committees. The report outlines a pay-for-performance executive compensation program for 2025, where most executives received 105% of target bonuses, while the CEO accepted 52.5% of target. The long-term incentives emphasize performance stock units tied to relative total shareholder return and the company received strong stockholder support (over 94.8%) on its 2025 "say-on-pay" vote.
Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS
Cwm LLC significantly reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by selling 52,353 shares, retaining 41,880 shares valued at approximately $1.05 million. Despite this sale, institutional ownership remains high at 96.29%, with other firms like SG Americas Securities LLC increasing their positions. Analysts currently have a consensus "Hold" rating on Apellis Pharmaceuticals with an average price target of $34.89.
Apellis surges on $5.6B buyout deal with Biogen
The article reports that Apellis Pharmaceuticals saw a significant surge in its stock price following an announced $5.6 billion buyout deal with Biogen. This acquisition highlights a major transaction within the biotechnology and pharmaceutical sectors.
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
This article highlights Apellis Pharmaceuticals (APLS) as the most overbought healthcare stock as Q1 earnings continue. It notes that despite a significant year-to-date gain, the stock is currently trading below its 52-week high, suggesting potential volatility or a correction. The piece likely delves into the financial metrics and market sentiment contributing to this assessment.
Attachment
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) has announced the appointment of Adam Townsend as its new Chief Commercial Officer. The company is a clinical-stage biopharmaceutical firm focusing on developing therapies by inhibiting the complement system.
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
This article identifies Apellis Pharmaceuticals as the most overbought healthcare stock as Q1 earnings continue. It likely discusses factors contributing to this assessment, such as its recent price performance, valuation metrics, or analyst sentiment, especially in the context of the ongoing earnings season for the pharmaceutical industry. The article may also delve into potential implications for investors.
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apellis Pharmaceuticals Inc. to Biogen Inc., questioning whether the offered consideration of $41.00 per share in cash plus a contingent value right for SYFOVRE sales adequately values the company. KSF encourages shareholders who believe the transaction undervalues Apellis or wish to discuss their legal rights to contact them immediately, emphasizing the time-sensitive nature due to the tender offer structure.
Apellis (NASDAQ: APLS) CFO reports bona fide stock gifts
Apellis Pharmaceuticals CFO Timothy Eugene Sullivan reported two bona fide gift transfers of common stock, totaling 22,192 shares on April 17, 2026. One gift transferred 11,096 shares to The Timothy E Sullivan Irrevocable Trust of 2023. Following these gifts, Sullivan directly holds 140,945 shares and indirectly holds 71,492 shares through the trust, disclaiming beneficial ownership except for his pecuniary interest.
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. The law firm is evaluating whether the offer of $41.00 per share in cash plus a contingent value right for potential additional payments adequately values the Company. Shareholders who believe the transaction undervalues Apellis are encouraged to contact KSF for a legal consultation.
